Multidrug-Resistant Salmonella typhi: A Worldwide Epidemic

Since 1989, strains of Salmonella typhi resistant to chloramphenicol, ampicillin, and trimethoprim (i.e., multidrug-resistant [MDR] strains) have been responsible for numerous outbreaks in countries in the Indian subcontinent, Southeast Asia, and Africa. MDR strains have also been isolated with incr...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 24; no. Supplement-1; pp. S106 - S109
Main Authors Rowe, Bernard, Ward, Linda R., Threlfall, E. John
Format Journal Article Conference Proceeding
LanguageEnglish
Published Chicago, IL University of Chicago Press 01.01.1997
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Since 1989, strains of Salmonella typhi resistant to chloramphenicol, ampicillin, and trimethoprim (i.e., multidrug-resistant [MDR] strains) have been responsible for numerous outbreaks in countries in the Indian subcontinent, Southeast Asia, and Africa. MDR strains have also been isolated with increasing frequency from immigrant workers in countries in the Arabian Gulf, as well as in developed countries from returning travelers. In all MDR strains so far examined, multiple resistance has been encoded by plasmids of the H 1 incompatibility group. As a result of the widespread dissemination of such strains, chloramphenicol can no longer be regarded as the first-line drug for typhoid fever. Because strains are also resistant to ampicillin and trimethoprim, the efficacy of these antibiotics has also been impaired, and ciprofloxacin is now the drug of choice for typhoid fever. Chromosomally encoded resistance to ciprofloxacin has now been observed in a small number of strains isolated in the United Kingdom from patients returning from the Indian subcontinent, and in at least one case the patient did not respond to treatment with this antibiotic. It is regrettable that resistance to ciprofloxacin has now emerged in MDR S. typhi, and it is of paramount importance to limit the unnecessary use of this vital drug so that its efficacy should not be further jeopardized.
Bibliography:istex:49D4CCABB7057C9930D2095156E83A323963E49B
Reprints or correspondence: Dr. E. John Threlfall, WHO Collaborating Centre for Phage Typing and Drug Resistance in Enterobacteria, Laboratory of Enteric Pathogens, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, United Kingdom.
ark:/67375/HXZ-F5N02TKS-Q
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1058-4838
1537-6591
DOI:10.1093/clinids/24.Supplement_1.S106